Law.com Subscribers SAVE 30%
Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
State-Law Design-Defect Claims Against Generic Drug Manufacturers Are Preempted
In 2011, the U.S. Supreme Court held that federal law prohibits generic pharmaceutical manufacturers from independently changing the labeling of their drugs ' the labeling must be the same as the labeling for the brand-name drug to which the generic is equivalent. PLIVA, Inc. v. Mensing, 131 S. Ct. 2567, 2574-77 (2011). State-law claims based on the failure to provide different warnings for generic drugs conflict with this “federal duty of 'sameness'” and are therefore preempted. Id. at 2575.
Although attempts to avoid Mensing have been largely unsuccessful, in Bartlett v. Mutual Pharm. Co., the First Circuit held that a design-defect claim against a generic manufacturer was not preempted under Mensing because it could simply “choose not to make the drug at all.” 678 F.3d 30, 37 (1st Cir. 2012). In June, the Supreme Court reversed, holding that “state-law design-defect claims ' that place a duty on [generic] manufacturers to render a drug safer by either altering its composition or altering its labeling are in conflict with federal laws that prohibit manufacturers from unilaterally altering drug composition or labeling.” Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466, 2479 (2013).
This premium content is locked for Entertainment Law & Finance subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Corporate Enforcement Policy: One Year Later
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Use of Deferred Prosecution Agreements In White Collar Investigations
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
How AI Has Affected PR
When we consider how the use of AI affects legal PR and communications, we have to look at it as an industrywide global phenomenon. A recent online conference provided an overview of the latest AI trends in public relations, and specifically, the impact of AI on communications. Here are some of the key points and takeaways from several of the speakers, who provided current best practices, tips, concerns and case studies.
New York's Latest Cybersecurity Commitment
On Aug. 9, 2023, Gov. Kathy Hochul introduced New York's inaugural comprehensive cybersecurity strategy. In sum, the plan aims to update government networks, bolster county-level digital defenses, and regulate critical infrastructure.